Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Spotify.
Pharrel Wiliams/iStock via Getty Images
Up for a challenge? Test your knowledge on the biggest events in the investing world over the past week. Take the latest Seeking Alpha News Quiz and see how you stack up against the competition.
Wall Street heads into the new week with a heavy slate of earnings, geopolitical developments, and key macro data likely to drive trading.
Earnings season accelerates, with Tesla (TSLA) in focus on Wednesday. Investors will be watching for updates on its AI5 chip timeline, robotaxi rollout, and capital spending plans. Intel (INTC) reports Thursday, with attention on margins and AI-driven demand, while other major names due this week include IBM (IBM), Texas Instruments (TXN), Boeing (BA), and American Express (AXP).
Economic data will also be in focus, highlighted by the March retail sales report on Tuesday and the University of Michigan consumer sentiment reading on Friday.
In tech, Google’s (GOOG) Cloud Next conference and Adobe’s (ADBE) Summit will spotlight AI developments, while a Senate hearing for Fed chair nominee Kevin Warsh adds a policy dimension.
Earnings spotlight: Monday, April 20: Steel Dynamics (STLD). See the full earnings calendar.
Earnings spotlight: Tuesday, April 21: GE Aerospace (GE), 3M (MMM), Halliburton (HAL), United Airlines (UAL). See the full earnings calendar.
Earnings spotlight: Wednesday, April 22: Tesla (TSLA), Philip Morris (PM), IBM (IBM), Boeing (BA). See the full earnings calendar.
Earnings spotlight: Thursday, April 23: Intel (INTC), American Express (AXP), Blackstone (BX). See the full earnings calendar.
Earnings spotlight: Friday, April 24: P&G (PG). See the full earnings calendar.
In case you missed it
Morgan Stanley maps 60 stocks across the space trade
Goldman rebalances its long duration stock basket
Power stocks with AI tailwinds
Top non-software secular growth stocks
Hank Paulson sounds alarm on vicious Treasuries selloff
Microsoft stock climbs in historic multi-day rally
Jonathan Faison leads the ROTY Biotech Community, an Investing Group built on over 18 years of biotech investing experience. His service brings together 480+ members, offering model portfolios, high-conviction ideas, and a highly active, collaborative chat environment.
Take a look at his latest idea:
(Free Full Article) Shares of Iovance Biotherapeutics have fallen significantly since the approval of Amtagvi in early 2024, despite earlier gains driven by optimism around its commercial rollout and pipeline progress. The recent decline is partly due to competitive concerns, especially ahead of a key decision for a rival therapy.
However, the overall outlook remains encouraging. Real-world data for Amtagvi shows stronger response rates than initial trials, which could support broader adoption, particularly in earlier-line melanoma patients. Financial performance is also improving, with rising revenues, better margins, and sufficient cash runway into 2027.
The company’s pipeline adds further upside, with opportunities in lung cancer and sarcoma showing promising early results. Management highlighted growing demand, expanding treatment networks, and ongoing global expansion efforts.
While risks such as potential dilution, competition, and clinical uncertainty remain, the company appears to be transitioning into a more stable growth phase. The current pullback may offer an entry point for investors comfortable with biotech volatility.
ROTY Biotech Community helps investors navigate the biotech sector with a disciplined, high-conviction approach focused on risk management and long-term growth. Members get full access to model portfolios, actionable research, trade ideas, and a highly active chat with direct interaction with Jonathan Faison and the community. Start with a 14-day free trial and take advantage of a limited-time 20% introductory discount, allowing you to subscribe at just $399.20. Learn more >>
What SA Analysts Are Watching
Tesla Earnings Preview: Why The Dream Is Breaking Down
S&P 500: The New High Fits The Trendline
Playing Iranian Roulette: Investors Are Asking The Wrong Questions
Why Geopolitical Risk Still Matters In An All-Time High Market
Boeing’s Shaping Up, But It’s Too Early To Hop On Board
AT&T Before The Bell: 5 Key Metrics To Watch